# Katherine Bowdish

> Katherine (Kathy) Bowdish is a molecular geneticist and biopharmaceutical leader who serves as President and CEO of PIC Therapeutics, a Natick, Massachusetts biotech developing cancer drugs that work by modulating RNA translation - targeting the eIF4E 'master switch' that tumors use to overproduce oncogene proteins. Over more than two decades she has founded and led a string of early-stage life science companies including Prolifaron (acquired by Alexion), Anaphore and Permeon Biologics, and she built and ran Sanofi Sunrise, the pharma giant's early-stage venture and partnering arm. She holds a PhD in molecular genetics from Columbia and led PIC through a $35 million Series A to push its lead program toward the clinic in drug-resistant breast cancer.

- **Role:** President & CEO at PIC Therapeutics
- **Organizations:** PIC Therapeutics, Sanofi, Permeon Biologics, Anaphore, Alexion Pharmaceuticals, Prolifaron
- **Nationality:** American
- **Education:** B.Sc. in Biology, College of William and Mary, PhD in Molecular Genetics, Columbia University College of Physicians and Surgeons, Postdoctoral research, UCLA
- **Known for:** Founded Prolifaron, an antibody-technology innovator that grew through pharma partnerships and was acquired by Alexion Pharmaceuticals, Co-founded and led Anaphore, developing the Atrimers class of trivalent protein pharmaceuticals, Launched and led Sanofi Sunrise, a venture investment and partnering vehicle at Sanofi

## Career timeline

- **1990s** — Founded Prolifaron, an antibody-technology company later acquired by Alexion Pharmaceuticals
- **2000s** — Served as President of Alexion Antibody Technologies and SVP of antibody discovery at Alexion Pharmaceuticals
- **2000s** — Co-founded and led Anaphore as President and CEO, pioneering Atrimers trivalent protein pharmaceuticals
- **2012** — Appointed President and Chief Scientific Officer of Permeon Biologics
- **2013** — Joined Sanofi; became VP and Head of R&D Strategy and launched Sanofi Sunrise venture arm
- **2020** — Appointed President, CEO and Director of PIC Therapeutics
- **2022** — Led PIC Therapeutics through a $35 million Series A financing led by OrbiMed

## Achievements

- Founded Prolifaron, an antibody-technology innovator that grew through pharma partnerships and was acquired by Alexion Pharmaceuticals
- Co-founded and led Anaphore, developing the Atrimers class of trivalent protein pharmaceuticals
- Launched and led Sanofi Sunrise, a venture investment and partnering vehicle at Sanofi
- Led PIC Therapeutics through a $35 million Series A financing in October 2022
- Advanced PIC's first-in-mechanism eIF4E translation modulator toward first-in-human clinical studies
- Served on the boards of biotech companies including MyoKardia, Warp Drive Bio, Portal Instruments and Thermalin

## Latest updates

- **2022-10** — PIC Therapeutics closed a $35 million Series A led by OrbiMed to advance its eIF4E translation modulator toward first-in-human studies in advanced metastatic breast cancer.
- **2020-08** — Appointed President, CEO and Director of PIC Therapeutics.

## Links

- Website: https://pictherapeutics.com
- LinkedIn: http://www.linkedin.com/in/kbowdish

---

Profile page: https://yespress.io/katherine-bowdish
Published by YesPress — https://yespress.io
Last updated: 2026-07-16